Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 851 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Food-effect Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy Volunteers

NCT04705922
View directory record Official record
Conditions
Healthy
Interventions
TT-00420 Capsule, TT-00420 Tablet
Drug
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Phase 1 Interventional

A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

NCT00821054
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Buffalo, New York • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

NCT05988021
View directory record Official record
Conditions
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
CCX168
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food-Effect Pharmacokinetic Study of PL2200

NCT01244100
View directory record Official record
Conditions
Healthy
Interventions
PL2200 fasted, PL2200 fed
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2010 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

NCT06181084
View directory record Official record
Conditions
Healthy
Interventions
LY3410738, Esomeprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults

NCT07622433
View directory record Official record
Conditions
Healthy Participants
Interventions
Laroprovstat/ezetimibe FCDP, Laroprovstat STP, Ezetimibe STP, Laroprovstat/ezetimibe FCDP-slow variant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 24, 2026, 6:39 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

NCT06989840
View directory record Official record
Conditions
Acne
Interventions
TVB-3567, Placebo
Drug
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3023414 Formulations and the Effect of Food

NCT02818335
View directory record Official record
Conditions
Healthy
Interventions
LY3023414 Reference Fasted, LY3023414 Test Fasted, LY3023414 Test Fed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

NCT01686217
View directory record Official record
Conditions
Pharmacokinetics of ASP015K, Food Effect, Healthy Volunteers
Interventions
ASP015K ER, ASP015K IR
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 24, 2026, 6:39 AM EDT
Withdrawn Phase 2 Interventional

Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery

NCT03488147
View directory record Official record
Conditions
Dysphagia, GERD, Degenerative Joint Disease
Interventions
Esomeprazole, Placebo Oral Tablet
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects

NCT00404963
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
placebo, GSK376501
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Nutrition Labeling on Fast Food Choices

NCT00127660
View directory record Official record
Conditions
Healthy
Interventions
Menu: calories=yes, value pricing=no, Menu: calories=yes, value pricing = yes, Menu: calories=no, value pricing = no
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years and older
Enrollment
605 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 24, 2026, 6:39 AM EDT
Not listed Phase 2 Interventional

A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD)

NCT03644069
View directory record Official record
Conditions
Celiac Disease, Celiac, Intestinal Disease, Malabsorption Syndromes, Gastrointestinal Disease, Digestive System Disease, Gluten Sensitivity, Autoimmune Diseases
Interventions
Nexvax2, Placebo
Biological
Lead sponsor
ImmusanT, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Walnut Creek, California • Stamford, Connecticut • Lighthouse PT, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 24, 2026, 6:39 AM EDT
Not yet recruiting Phase 1 Interventional

Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes

NCT07772960
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30)
Interventions
Placebo, Semaglutide 1.0 mg, Semaglutide 2.0 mg
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 68 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.

NCT00812318
View directory record Official record
Conditions
HIV Infection, Infection, Human Immunodeficiency Virus
Interventions
GSK1265744 10 mg oral solution, GSK1265744 5 mg tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of the Potential Impact of a High-fat Meal on the Pharmacokinetics of CRS3123 in Healthy Adult Participants

NCT06988423
View directory record Official record
Conditions
Food Effect in Healthy Participants
Interventions
CRS3123 200 mg capsule
Drug
Lead sponsor
Crestone, Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects

NCT04838639
View directory record Official record
Conditions
Obesity
Interventions
NO-13065, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Factory, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 BIO 300 Oral Suspension

NCT06741345
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
BIO 300 Oral Suspension
Drug
Lead sponsor
Humanetics Corporation
Industry
Eligibility
18 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Dietary Supplement Containing L-Arabinose and Trivalent Patented Food-source of Chromium on Blood Glucose and Insulin

NCT01107431
View directory record Official record
Conditions
Pre-diabetes
Interventions
L-Arabinose and Chromium, Sucrose without dietary Supplement
Dietary Supplement
Lead sponsor
Integrative Health Technologies, Inc.
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Oct 24, 2026, 6:39 AM EDT
Not listed Not applicable Interventional

Hepaxa Management of Non-alcoholic Fatty Liver Disease

NCT03801577
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, NASH - Nonalcoholic Steatohepatitis
Interventions
Hepaxa
Dietary Supplement
Lead sponsor
BASF AS
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Flowood, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Function and Energy Levels

NCT07755475
View directory record Official record
Conditions
Cognitive Function, Fatigue, Energy Levels, Mental Clarity, Brain Fog, Food Cravings
Interventions
Cellular Hydration Supplement
Dietary Supplement
Lead sponsor
Artah Nutrition Limited
Industry
Eligibility
25 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Breakfast and Metabolism in Men

NCT03399812
View directory record Official record
Conditions
Aging
Interventions
Animal protein, Plant protein
Dietary Supplement
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Phase 1 Interventional

Ro 31-7453 in Treating Patients With Metastatic Solid Tumors

NCT00014365
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
MKC-1
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 24, 2026, 6:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension

NCT02641353
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Apremilast Tablet, Apremilast Oral Suspension
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 24, 2026, 6:39 AM EDT